AHA on July 21 submitted comments on how Congress can ensure that the 340B program continues to benefit patients and communities, while acting to prevent any cuts to the program that would jeopardize patient access to care. Responding to a bipartisan request by senators for input, AHA strongly urged that the Health Resources and Services Administration finalize its Administrative Dispute Resolution rule for the 340B program and explicitly state that the ADR process is an available forum for affected 340B hospitals to seek redress from restrictions targeted to community and specialty pharmacies. AHA also recommended that Congress require HRSA to increase its annual audits of drug companies in the 340B program, which average six per year compared with over 200 per year for 340B covered entities, and give hospitals and other covered entities the ability to audit drug manufacturers.

Related News Articles

Headline
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s…
Headline
The anticipated burdens on hospitals to comply with the Health Resources and Services Administration’s 340B Rebate Pilot Program far exceed the agency’s…
Headline
The U.S. District Court for the District of Maine today issued an order denying preliminary injunctions requested by AbbVie and Novartis in legal challenges…
Headline
The AHA commented Sept. 15 on the Centers for Medicare & Medicaid Services calendar year 2026 outpatient prospective payment system and ambulatory surgical…
Headline
The United States Court of Appeals for the Fifth Circuit Sept. 12 affirmed a Mississippi Court’s decision to deny AbbVie’s request for a preliminary injunction…
Headline
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…